Aliakbar Delbandi

Dr. Aliakbar Delbandi


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 November 2020 in Reproductive BioMedicine Online
Verified
Journal Article
Closed access
HYHadi Mohagheghian Yaghoubi
Hadi Mohagheghian Yaghoubi
MSMorteza Samadi
Morteza Samadi
NTNader Tajik
Nader Tajik
PBPegah Babaheidarian
Pegah Babaheidarian
SMSajjadeh Movahedinia
Sajjadeh Movahedinia
ADAliakbar Delbandi
Aliakbar Delbandi

19 September 2023 in Frontiers in Nutrition
Verified
Journal Article
Open access
SKSahar Jafari Karegar
Sahar Jafari Karegar
NANaheed Aryaeian
Naheed Aryaeian
GHGhazaleh Hajiluian
Ghazaleh Hajiluian
KSKatsuhiko Suzuki
Katsuhiko Suzuki
FSFarzad Shidfar
Farzad Shidfar
ADAliakbar Delbandi
Aliakbar Delbandi
Background: Multiple sclerosis (MS) is a chronic autoimmune disease. Ellagic acid is a natural polyphenol and affects the fate of neurons through its anti-inflammatory and antioxidant properties. The present study aimed to investigate ellagic acid effects on disease severity, the expression of involved genes in the pathogenesis of MS, and the levels of related cytokines.Methods: The present study was a triple-blind clinical trial. Eligible patients were randomly assigned to two groups: Ellagic acid (25 subjects) for 12 weeks, receiving 180 mg of Ellagic acid (Axenic, Australia) and the control group (25 subjects) receiving a placebo, before the main meals. Before and after the study, the data including general information, foods intake, physical activity, anthropometric data, expanded disability status scale (EDSS), general health questionnaire (GHQ) and pain rating index (PRI), fatigue severity scale (FSS) were assessed, as well as serum levels of interferon-gamma (IFNγ), interleukin-17 (IL-17), interleukin-4 (IL-4) and transforming growth factor-beta (TGF-β), nitric-oxide (NO) using enzyme-linked immunoassay (ELISA) method and expression of T-box transcription factor (Tbet), GATA Binding Protein 3 (GATA3), retinoic acid-related orphan receptor-γt (RORγt) and Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) genes were determined using Real-Time Quantitative Reverse Transcription PCR (RT-qPCR) method.Findings: Ellagic acid supplementation led to a reduction in IFNγ, IL-17, NO and increased IL-4 in the ellagic acid group, however in the placebo group no such changes were observed (−24.52 ± 3.79 vs. -0.05 ± 0.02, p < 0.01; −5.37 ± 0.92 vs. 2.03 ± 1.03, p < 0.01; −18.03 ± 1.02 vs. -0.06 ± 0.05, p < 0.01, 14.69 ± 0.47 vs. -0.09 ± 0.14, p < 0.01, respectively). Ellagic acid supplementation had no effect on TGF-β in any of the study groups (p > 0.05). Also, the Tbet and RORγt genes expression decreased, and the GATA3 gene expression in the group receiving ellagic acid compared to control group significantly increased (0.52 ± 0.29 vs. 1.51 ± 0.18, p < 0.01, 0.49 ± 0.18 vs. 1.38 ± 0.14, p < 0.01, 1.71 ± 0.39 vs. 0.27 ± 0.10, p < 0.01). Also, ellagic acid supplementation led to significant decrease in EDSS, FSS and GHQ scores (p < 0.05), and no significant changes observed in PRI score (p > 0.05).Conclusion: Ellagic acid supplementation can improve the health status of MS patients by reduction of the inflammatory cytokines and Tbet and RORγt gene expression, and increment of anti-inflammatory cytokines and GATA3 gene expression.Clinical trial registration: (https://en.irct.ir/trial/53020), IRCT20120415009472N22.

8 January 2021 in Immunological Investigations
Verified
Journal Article
Closed access
MRMaryam Roomiani
Maryam Roomiani
FFFatemeh Dehghani Firouzabadi
Fatemeh Dehghani Firouzabadi
ADAliakbar Delbandi
Aliakbar Delbandi
BGBabak Ghalehbaghi
Babak Ghalehbaghi
ADAhmad Daneshi
Ahmad Daneshi
AAAlimohamad Asghari
Alimohamad Asghari
A few studies investigated the relationship between allergy and Meniere disease considering complete allergen panel. We aimed to evaluate the serum immunoreactivity in patients with Meniere’s disea...

17 April 2025 in Multiple Sclerosis Journal – Experimental, Translational and Clinical
Verified
Journal Article
Open access
SKSahar Jafari Karegar
Sahar Jafari Karegar
AMAbasat Mirzaei
Abasat Mirzaei
GHGhazaleh Hajiluian
Ghazaleh Hajiluian
NANaheed Aryaeian
Naheed Aryaeian
FSFarzad Shidfar
Farzad Shidfar
ADAliakbar Delbandi
Aliakbar Delbandi
Background: This study aimed to evaluate the impact of ellagic acid (EA) on fatigue, depression, and anxiety in patients with multiple sclerosis (MS) who have moderate disability. Methods: A triple-blind, placebo-controlled clinical trial was conducted. Fifty-eight MS patients were randomly allocated to receive EA or placebo. Measurements of fatigue, depression, and anxiety were taken at the beginning and end of the study. Data analysis was performed via SPSS. Results: Significant improvements were observed in the EA group across several measures: the State-Trait Anxiety Inventory (STAI), the Quick Inventory of Depressive Symptomatology (QIDS), the Hospital Anxiety and Depression Scale (HADS) for both depression and anxiety subscales, and the Modified Fatigue Impact Scale (MFIS), which includes total, cognition, psychosocial, and physical scores (P < 0.001). At the end of the study, significant differences between the EA and placebo groups were noted. Within the EA group, significant changes from baseline were found in EDSS, STAI (p = 0.003), QIDS (p = 0.041), HADS-D (p = 0.032), HADS-A (p = 0.012), total MFIS (p = 0.004), MFIS-Cognition (p = 0.001), MFIS-Psychosocial (p = 0.049), and MFIS-physical (p = 0.001) scores. In the EA group, significant changes from baseline were observed in EDSS, STAI (p = 0.003), QIDS (p = 0.041), HADS-D (p = 0.032), HADS-A (p = 0.012), total MFIS (p = 0.004), MFIS-Cognition (p = 0.001), MFIS-Psychosocial (p = 0.049), and MFIS-physical (p = 0.001) scores. Conclusions: EA appears to significantly alleviate fatigue, depression, and anxiety in MS patients.